Loading...
Loading...
Celldex Therapeutics, Inc.
CLDX today announced positive results
demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in
solid tumors in combination with the toll-like receptor (TLR) agonists
resiquimod and/or Poly ICLC (Hiltonol^TM). CDX-1401 is a fusion protein
consisting of a fully human monoclonal antibody with specificity for the
dendritic cell receptor DEC-205 linked to the NY-ESO-1 tumor antigen. The
NY-ESO-1 antigen is expressed in a variety of cancer cells. Targeting protein
antigens to the DEC-205 receptor on dendritic cells was pioneered by the late
Ralph Steinman, MD, a member of Celldex's Scientific Advisory Board. Dr.
Steinman received the 2011 Nobel Prize in Physiology or Medicine for his
discovery of the dendritic cell and its role in adaptive immunity. In
preclinical studies, CDX-1401 has been shown to induce potent and broad
immunity. The Phase 1 study of CDX-1401 is the first clinical study to
demonstrate that an off-the-shelf vaccine that targets dendritic cells in vivo
through DEC-205 can safely lead to robust humoral and cellular immunity when
combined with TLR agonists in cancer patients - overcoming a significant
challenge in the development of protein based vaccines.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in